This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pazopanib for soft tissue sarcoma, advanced – second line

< Back

Pazopanib for soft tissue sarcoma, advanced – second line


Cancer and Palliative Care

December 2010

Pazopanib hydrochloride (GW 786034; GW786034B; SB 786034; Votrient) is an oral multi-targeted tyrosine kinase receptor inhibitor with anti-tumour activity. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR) 1, -2 and -3; platelet derived growth factor receptor (PDGFR); and c-kit; which may result in inhibition of angiogenesis in tumours in which these receptors are upregulated. It is intended to treat patients with advanced STS when prior chemotherapy has failed, is contraindicated, or refused by patients. Pazopanib is administered at 800mg once daily as monotherapy until disease progression or unacceptable toxicity.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts